A very timely conference
I wonder what the turnout will be
Susquehanna Financial Group’s
Toll-Like Receptor Conference
Thursday, July 12, 2007
Conference Details
What:
Navigating the Toll Road: Understanding the Next Paradigm in Immune Modulation and its Implications in Cancer, Autoimmune and Infectious Disease
When:
Thursday, July 12, 2007
10:00am – 1:00pm
Where:
InterContinental, The Barclay NY
111 East 48th St. (Lexington/Park Ave)
New York, NY 10017
212-755-5900
The SFG Biotechnology Team is hosting this unique opportunity for investors to learn about the therapeutic potential of one of the newest and most cutting edge classes of drugs, the toll-like receptor (TLR) modulators. Hear from Key Opinion Leaders from academia as well as representatives from the industry.
Gain insight into:
The pros and cons of TLR immunomodulation compared to classical immunmodulatory pathways (cancer vaccines, interleukins and interferons)
The differential effects of targeting TLR7, TLR8 and TLR9
How formulation and pharmacokinetics affect the level of stimulation/inhibition of TLRs
The utility of targeting TLRs to treat cancer, autoimmune and infectious diseases
The advantages and disadvantages of using oligonucleotide vs. small molecule-based targeting
ATTENDING COMPANIES & EXPERTS
Anadys Pharmaceuticals
President, Pharmaceuticals, Stephen Worland, PhD
Coley Pharmaceutical Group
President & CEO, Robert Bratzler, PhD
Senior VP, R&D & Chief Scientific Officer, Arthur Krieg, MD
Dynavax Technologies Corporation
VP, Chief Business Officer & General Counsel, Michael Ostrach
VP & Chief Scientific Officer, Robert Coffman, PhD
Idera Pharmaceuticals, Inc
CEO & Chief Scientific Officer, Sudhir Agrawal, DPhil
President, Robert W. Karr, MD
Formal Invitation to follow with agenda, presenters and registration details.
To register please contact your SIG Salesperson or
Lori Aversano at Lori.Aversano@sig.com
